Presentation to Australian Biologics Festival 2024
Released
Released
Announcement PDF
Australian Biologics Festival 2024
Melbourne, Australia, February 21, 2024: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian
based and globally integrated biopharmaceutical company is pleased to advise our Research &
Development Manager, Joanne Casey, PhD will be presenting at the Australian Biologics Festival 2024 on
Wednesday, 21st February in Melbourne, Australia.
A copy of the presentation being made is included below.
Authorised for release by the Board of Immuron Limited.
COMPANY CONTACT:
Steven Lydeamore
Chief Executive Officer
Ph: +61 (0)3 9824 5254
info@immuron.com
- - - END - - -
About Travelan®
Travelan® is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting traveller’s
diarrhoea, a digestive tract disorder that is commonly caused by pathogenic bacteria and the toxins they produce. Travelan® is a
highly purified tabletised preparation of hyperimmune bovine antibodies and other factors, which when taken with meals bind to
diarrhoea-causing bacteria and prevent colonisation and the pathology associated with traveller’s diarrhoea. In Australia,
Travelan® is a listed medicine on the Australian Register for Therapeutic Goods (AUST L 106709) and is indicated to reduce the risk
of Traveller’s Diarrhoea, reduce the risk of minor gastrointestinal disorders and is antimicrobial. In Canada, Travelan® is a licensed
natural health product (NPN 80046016) and is indicated to reduce the risk of Traveller’s Diarrhoea. In the U.S., Travelan® is sold as
a dietary supplement for digestive tract protection.
About Traveller’s Diarrhoea
Traveller’s Diarrhoea is a gastrointestinal infection with symptoms that include loose, watery (and occasionally bloody) stools,
abdominal cramping, bloating, and fever, Enteropathogenic bacteria are responsible for most cases, with enterotoxigenic
Escherichia coli (ETEC) playing a dominant causative role. Campylobacter spp. are also responsible for a significant proportion of
cases. The more serious infections with Salmonella spp. the bacillary dysentery organisms belonging to Shigella spp. and Vibrio
spp. (the causative agent of cholera) are often confused with Traveller’s Diarrhoea as they may be contracted while travelling and
initial symptoms are often indistinguishable.
About Immuron
Immuron Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and
commercialising orally delivered targeted polyclonal antibodies for the treatment of infectious diseases.
For more information visit: http://www.immuron.com
FORWARD-LOOKING STATEMENTS:
This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934, each as amended. Such statements include, but are not limited to, any statements relating to our growth strategy and product development
programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to
risks and uncertainties that could negatively affect our business, operating results, financial condition and stock value. Factors that could cause actual results to
differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under and maintain financing and
strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the timing of starting and completing
clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key
personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property
matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on
which any such statement is based, except as required by law.
2ND AUSTRALIAN BIOLOGICS
FESTIVAL 2024
NAVIGATING NEW HORIZONS:
TRAVELAN ® MARKET EXPANSION INTO THE
USA
STRATEGIC COLLABORATIONS, PARTNERSHIPS
AND CLINICAL TRIALS
JERRY KANELLOS, PhD
Chief Scientific Officer
Presented by:
JOANNE CASEY, PhD
R&D Manager
NASDAQ: IMRN
1
ASX: IMC
SAFE HARBOR STATEMENT
C e r ta i n state m e n t s m a d e i n t h i s p re s e nta t i o n a re fo r wa rd - l o o k i n g state m e n t s a n d a re
b a s e d o n I m m u ro n ’s c u r re nt ex p e c tat i o n s , e st i m ate s a n d p ro j e c t i o n s . Wo rd s s u c h a s
“a nt i c i p a t e s ,” “ex p e c t s ,” “ i nte n d s ,” “ p l a n s ,” “ b e l i e ve s ,” “s e e ks ,” “e st i m a te s ,” “g u i d a n c e ”
a n d s i m i l a r ex p re s s i o n s a re i nte n d e d to i d e nt i f y fo r wa rd - l o o k i n g state m e n t s .
A l t h o u g h I m m u ro n b e l i e v e s t h e fo r wa rd - l o o k i n g state m e n t s a re b a s e d o n
re a s o n a b l e a s s u m p t i o n s , t h ey a re s u b j e c t to c e r ta i n r i s ks a n d u n c e r ta i n t i e s ,
s o m e o f w h i c h a re b eyo n d I m m u ro n ’s c o nt ro l , i n c l u d i n g t h o s e r i s ks o r
u n c e r ta i n t i e s i n h e re n t i n t h e p ro c e s s o f b o t h d e ve l o p i n g a n d c o m m e rc i a l i z i n g
te c h n o l o g y. A s a re s u l t , a c t u a l re s u l t s c o u l d m ate r i a l l y d i ffe r f ro m t h o s e
ex p re s s e d o r fo re ca ste d i n t h e fo r wa rd - l o o k i n g state m e n t s .
T h e fo r wa rd - l o o k i n g state m e n t s m a d e i n t h i s p re s e n ta t i o n re l ate o n l y to
e ve nt s a s o f t h e d ate o n w h i c h t h e state m e n t s a re m a d e . I m m u ro n w i l l n o t
u n d e r ta ke a ny o b l i gat i o n to re l e a s e p u b l i c l y a ny re v i s i o n s o r u p d ate s to
t h e s e fo r wa rd - l o o k i n g state m e n t s to ref l e c t e ve nt s , c i rc u m sta n c e s o r
u n a nt i c i p a te d e ve nt s o c c u r r i n g a f te r t h e d ate o f t h i s p re s e nta t i o n exc e p t a s
re q u i re d b y l aw o r b y a ny a p p ro p r i a te re g u l ato r y a u t h o r i t y.
F Y 2 0 2 4 re s u l t s i n t h i s p re s e nta t i o n a re s u b j e c t to a u d i t re v i e w.
2
TOPICS
Introduction
• Immuron’s Pipeline Technology
• Travelan – commercial product
Partnering with US Department of Defense (DoD)
• History of collaborations
• DoD funding
Commercial pathway of Travelan® in the US
• FDA clinical pathway to BLA
• Scale-up Product Development
• Current status and future
3
Immuron Ltd is a globally integrated biopharmaceutical company focused on
developing, and commercialising, oral immunotherapeutics for the treatment of gut
mediated diseases
Dual listed (ASX:IMC) (NASDAQ:IMRN)
Company
Overview
➢
Platform Technology: capable of producing highly specific orally active immunoglobulins to any
enteric pathogen
➢
Two commercially available oral immunotherapeutic products – Travelan® and Protectyn®
➢
Three pipeline assets in four clinical programs
4
PLATFORM TECHNOLOGY
Bovine colostrum is the first milk of cows after calving. It is rich in immunoglobulins, lactoferrin, lysozyme, lactoperoxidase,
growth factors and bioactive peptides. Colostrum has higher levels of protein, fat, vitamins, and minerals when compared to
milk. This enables full development of the newborn calf in addition to immunity against several pathogens.*
Immuron’s proprietary technology platform combines the natural human nutrition & health benefits of bovine colostrum with
a novel class of specifically targeted oral polyclonal antibodies that offer delivery within the gastrointestinal (“GI”) tract and
can be used to target viruses or bacteria and neutralize the toxins they produce at mucosal surfaces.
STEP 1
Development of Highly
Specific Vaccines
STEP 2
Isolation of Hyperimmune
antibody-rich
bovine colostrum
* Gomes et. al., NFS Journal, Volume 25, November 2021, pages 111, https://doi.org/10.1016/j.nfs.2021.10.001
STEP 3
Oral Antimicrobial
therapeutics
without drawbacks
of antibiotics
FINAL PRODUCT
Toxin Neutralization +
Clearance of targeted gut
pathogens
5
INTELLECTUAL PROPERTY
Due to the practical nature of the technology used to produce our products, the company retains a significant amount of knowhow and other unregistered intellectual property which presents significant hurdles to competitors in producing the same
products. The company has a policy of actively in-licensing and filing upon new technology that relates to all relevant business
objectives.
Immuron currently has a suite of patents either approved or pending that cover the full spectrum of its Technology Platform.
METHODS AND COMPOSITIONS FOR THE TREATMENT AND/OR PROPHYLAXIS OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASE
Granted (Expiry: April 17, 2034): Australia, New Zealand, Canada, USA, Belgium, France, Germany, Italy, Netherlands, Spain,
Switzerland, United Kingdom
Pending: China
COMPOSITION AND METHOD FOR THE TREATMENT AND PREVENTION OF ENTERIC BACTERIAL INFECTIONS
Granted (Expiry: February 25, 2028): USA
Granted (Expiry: March 4, 2024): Australia, Canada, India, New Zealand, Austria, Denmark, Finland, France, Germany, Greece,
Spain, Sweden, United Kingdom
6
BILLION DOLLAR MARKET
- INDUSTRY OVERVIEW
Billion Dollar Market
Travellers’ diarrhoea treatment market
is large and growing at a CAGR of ~7%
Industry tailwinds
Travel picking up significantly following
COVID lockdowns
Frequent Symptoms
30% - 70% of travelers experience travellers’ diarrhoea1
•
There are no current reliable vaccines for prevention of Travellers’ diarrhoea1
•
Enterotoxigenic Escherichia coli (ETEC) is the leading cause of Travellers’ diarrhoea1
•
Travelan® is a hyperimmune bovine colostrum produced by immunization of cows during
gestation with a vaccine consisting of antigens derived from 13 different ETEC strains known to
cause Travelers’ diarrhea
•
Travelan® is broadly cross-reactive with other ETEC strains not included in the vaccine and other
gram-negative bacteria (Shigella, Vibrio cholera, Campylobacter spp.)2,3
1 Centers for Disease Control and Prevention CDC.gov 2024
2 Sears et al., Clin. Vaccine Immunol. 2017 https://doi.org/10.1128/cvi.00186-16
3 Islam et al., PLOS one 2023 https://doi.org/10.1371/journal.pone.0294021
7
PLOS ONE
RESEARCH ARTICLE
Bioactivity and efficacy of a hyperimmune bovine colostrum product - Travelan, against shigellosis in a nonHuman primate model (Macaca mulatta).
Abstract
Infectious diarrhea is a World Health Organization public health priority area due to the lack of effective vaccines and an accelerating global
antimicrobial resistance crisis. New strategies are urgently needed such as immunoprophylactic for prevention of diarrheal diseases.
Hyperimmune bovine colostrum (HBC) is an established and effective prophylactic for infectious diarrhea. The commercial HBC product, Travelan®
(Immuron Ltd, Australia) targets multiple strains of enterotoxigenic Escherichia coli (ETEC) is highly effective in preventing diarrhea in human
clinical studies. Although Travelan® targets ETEC, preliminary studies suggested cross-reactivity with other Gram-negative enteric pathogens
including Shigella and Salmonella species. For this study we selected an invasive diarrheal/dysentery-causing enteric pathogen, Shigella, to
evaluate the effectiveness of Travelan®, both in vitro and in vivo. Here we demonstrate broad cross-reactivity of Travelan® with all four Shigella
spp. (S. flexneri, S. sonnei, S. dysenteriae and S. boydii) and important virulence factor Shigella antigens. Naïve juvenile rhesus macaques (NJRM)
were randomized, 8 dosed with Travelan® and 4 with a placebo intragastrically twice daily over 6 days. All NJRM were challenged with S. flexneri 2a
strain 2457T on the 4th day of treatment and monitored for diarrheal symptoms. All placebo-treated NJRM displayed acute dysentery symptoms
within 24–36 hours of challenge. Two Travelan®-treated NJRM displayed dysentery symptoms and six animals remained healthy and symptom-free
post challenge; resulting in 75% efficacy of prevention of shigellosis (p = 0.014).
These results strongly indicate that Travelan® is functionally cross-reactive and an effective prophylactic for shigellosis. This has positive
implications for the prophylactic use of Travelan® for protection against both ETEC and Shigella spp. diarrheal infections. Future refinement and
expansion of pathogens recognized by HBC including Travelan® could revolutionize current management of gastrointestinal infections and
outbreaks in travelers’ including military, peacekeepers, humanitarian workers and in populations living in endemic regions of the world.
Islam et al., PLOS one 2023 https://doi.org/10.1371/journal.pone.0294021
8
TRAVELAN®
➢ Travelan® is a pasteurized, lactose-reduced, low-fat, high-protein colostrum
powder which contains over 80% proteins by weight.
➢ Travelan® is enriched with anti-Enterotoxigenic E.coli (ETEC) antibodies (35-45%
w/w), which target ETEC in the gastrointestinal tract
Australian Packaging
➢ Travelan® is a biological product intended to prevent Travellers’ Diarrhoea without
major alterations to the microbiome, unlike antibiotics
➢ Travelan® is the world’s first listed medicine (2004) on the Australian Register for
Therapeutic goods (TGA) indicated to reduce the risk of Travellers’ Diarrhoea (AUST
L 106709)
➢ Travelan® has been marketed in Canada since 2013 as a natural health product
(NPN 80046016) indicated to reduce the risk of TD
➢ Travelan® has been marketed since 2015 in the US as a dietary supplement for
digestive tract protection
USA Packaging
9
TRAVELAN DISTRIBUTION CAPABILITY
Australia
USA
Shandex
Canada
Ontario, Canada
Distributes to all
provinces of Canada
Retail Pharmacy
B2B
Established
E-commerce
Developing
Immuron Ltd
Vancouver, BC, Canada
Key Commentary
Australia
• Retail network includes over 3,500 pharmacies
• Online sales of both Travelan® and Protectyn®
• Protectyn® is distributed by Osborne Health Supplies
USA
• Travelan® is sold to travel medicine clinics and on our own amazon.com
shopfront (launched July 2023)
Canada
• We re-launched in January 2024
International
• We are evaluating options to enter international markets through
distributors
RJW Logistics
Immuron Inc.
Chicago, USA
Distributes to all
states of USA
New York, USA
Immuron Ltd
Melbourne, Australia
Distributes to all states of Australia and to distributors in USA
and Canada
10
TRAVELAN – MECHANISM OF ACTION
Pre-Clinical
Studies
• Broad spectrum antimicrobial (gram negative bacteria)
• Protects against bacterial adhesion to host cell intestinal epithelia
• Caesin and other colostrum proteins are known to protect the antibodies from the acid
environment of the stomach
• Binds to surface layer proteins preventing bacterial colonization and motility
• Toxin neutralization and clearance of targeted gut pathogens
Without Travelan®: Bacteria attach to gut
wall and infect
With Travelan®: Bacteria neutralized by
Travelan® antibodies
11
TRAVELAN® MANUFACTURING
Vaccine
➢ Manufacture involves proprietary shearing technology developed to harvest cell surface antigens from 13
Enterotoxigenic E. coli (ETEC) strains known to cause Travelers’ diarrhea
➢ Approved by performing a risk assessment for use in food-producing animals with the Australian Pesticides and
Veterinary Medicines Authority (APVMA)
➢ Manufactured under Good Manufacturing Practice (GMP) in a facility licensed by the APVMA
Colostrum
➢ Colostrum is collected from cattle on dairy farms using GMP-compliant collection and Manufacturing methods, using
Australian Dairy Industry approved proceduresand FDA guidelines
➢ Manufacturing Process: i) pasteurization, ii) separation of fat, iii) ultrafiltration to reduce lactose and concentrate the
product, and iv) spray-drying to produce a stable colostrum powder milled to 100 microns
➢ No chemical additives are used in the manufacturing process
➢ Colostrum Product analyzed for safety under Codex Alimentarius and FDA regulations for human consumption
12
MANUFACTURING TRAVELAN® - DRUG SUBSTANCE
13
MANUFACTURING – TRAVELAN® DRUG PRODUCT
➢ Tablets packaged in unit-dose blister packs containing 200 mg of bovine colostrum
formulated as a 700 mg solid oral dose tablet with non-novel excipients
➢ All excipients are within regulations of United States Pharmacopeia and National
Formulary
➢ Product specifications include i) IgG content, ii) antibody ETEC titer, iii) metal content
iv) microbiological sterility analysis
➢ Current FDA CMC requirements for Phase 2 Biologics (CBER)
Stability data
➢ 25oC - 48 month (real-time)
➢ 40oC / 75% RH – 12 month (real-time)
➢ Long term -20oC/4oC (real-time)
14
TRAVELAN® SAFETY AND EFFICACY
➢ Randomised, double-blind,
placebo-controlled human
infection model studies
➢ Travelan or placebo 200400mg 3 times daily for 7
days
➢ Challenge with ETEC 2 days
after dosing
84% to over 90% prophylactic efficacy in
the Travelan treatment arm
1Otto W, Najnigier B, Stelmasiak T, Robins-Browne RM. Randomized control trials using a tablet formulation of hyperimmune bovine colostrum to prevent diarrhea caused by enterotoxigenic Escherichia coli
in volunteers. Scand J Gastroenterol. 2011 Jul;46(7-8):862-8. doi: 10.3109/00365521.2011.574726. PMID: 21526980; PMCID: PMC3154584.
15
TRAVELAN® SAFETY
• Travelan® is well tolerated and has been administered orally in over 500 subjects in
clinical trials with doses up to 4.8 g per day for 28 days with no treatment related Serious
adverse events (SAEs)
• Clinically evaluated in Children (6 to 19 years of age)
• Pharmacovigilance has reported no product related SAEs to date
• Reported Adverse Events (AEs) are mild in severity (abdominal discomfort, bloating,
constipation, flatulence, nausea and occasionally diarrhea (usually related to lactose
intolerance)
16
NEW HORIZONS
EXPANSION INTO THE US
1. Collaboration with the US Department
of Defense (DOD)
2. FDA Clinical Pathway to approval of a
listed medicine
3. Immuron distribution and expansion
plans
17
TRAVELERS’ DIARRHEA AND THE US MILITARY
18
TRAVELERS’ DIARRHEA – CURRENT MANAGEMENT IN THE US
• The literature indicates that overall, ~50% of US travelers to remote or
less developed countries seek pre-travel guidance. Advice from
physicians, travel clinics, pharmacists, or other source.
• Physicians’ standard protocol for a patient traveling to a high-risk area is
the prescription of a 5-day course of an antibiotic (typically ciprofloxacin
or azithromycin) for the patient to fill and take if symptoms develop (e.g.,
diarrhea, fever).
• Concerned travelers are prescribed antibiotics to be taken prophylactically
19
US MILITARY – TRAVEL AND RISK
Key Commentary
• US Military Infectious Diseases
Research Program (MIDRP)
•
•
•
•
The mission of the MIDRP is to plan, coordinate
and oversee for the US DOD requirements-driven
medical solutions that PREVENT, PREDICT, and
TREAT infectious diseases threats
Diarrheal disease is the leading infectious threat
facing deployed U.S. Military
Effective vaccines are the most suitable preventive
measure for infectious diarrheal diseases but there
are no licensed products available
Enteric countermeasure products need to provide
protection against military-relevant enteric
pathogens
US Military Map – worldwide risk to US forces, APIS/I-92 MONITOR data (trade.gov)
20
US DOD R&D COLLABORATIVE AGREEMENTS
NMRC
AFRIMS
WRAIR
Travelan®(ETEC)
Campylobacter
Established
Shigella
Developing
Key Commentary
▪ Immuron history of collaboration with NMRC since 2015
ARMED FORCES RESEARCH INSTITUTE OF
MEDICAL SCIENCES (AFRIMS)
▪ R&D focused on diarrheal infectious agents: Campylobacter,
enterotoxigenic Escherichia coli (ETEC) and Shigella
▪ Historically focused on human vaccine development
▪ Several vaccines are in clinical evaluation
▪ No licensed vaccine products currently available
NAVAL MEDICAL RESEARCH COMMAND
(NMRC)
▪ US DoD R&D efforts diversified to evaluate prophylaxis products
UNIFORMED SERVICES UNIVERSITY
(USU)
21
The views expressed in this presentation are those of the author and do not necessarily reflect the official policy or position of the Department of the Army, Department of the Navy, Department of Defense, nor the U.S. Government
US DOD R&D COLLABORATIONS
Current clinical programs
NMRC
AFRIMS
WRAIR
Travelan® MTEC military grant (USD$3.4M) phase 2 clinical study
NCT05933525
Travelan®(ETEC)
Campylobacter
Established
Shigella
Developing
Travelan® - Uniformed Services University field study 868 participants
including deployed military NCT04605783
CampETEC (NMRC) – clinical phase 2 Campylobacter challenge study
NCT06122870
Key Highlights
▪ Immuron partnered with AFRIMS, NMRC & WRAIR to analyze Travelan® specificity against Campylobacter, ETEC, Shigella and Vibrio
cholera field samples (2016)
▪ Travelan® reacts with 180 pathogenic strains of bacteria from infected personnel deployed in Bhutan, Cambodia, Nepal and Thailand
(ETEC, Shigella, Campylobacter)
▪ Travelan® binds to 71 different pathogenic strains of Vibrio cholera from infected personnel in Bangladesh, Cambodia, and Thailand
▪ Travelan® prevented the development of Shigellosis in 75% of non-human primates receiving therapy
22
The views expressed in this presentation are those of the author and do not necessarily reflect the official policy or position of the Department of the Army, Department of the Navy, Department of Defense, nor the U.S. Government
PARTNERING WITH US DEPARTMENT OF DEFENSE
Co
MTEC Membership
Note: In order to respond to any solicitation
on this site, you must be a member of the MTEC
Consortium.
Solicitations include awards from:
Military Infectious Diseases Research Program (MIDRP)
Combat Casualty Care Research Program (CCCRP)
Military Operational Medicine Research Program
(MOMRP)
Clinical and Rehabilitative Medicine Research Program
(CRMRP)
Medical Simulation and Information Sciences Research
Program (MSISRP)
• Join funding consortiums like MTEC which the U.S. Army Medical Research
and Development Command (USAMRDC) and other DoD agencies offer
funding opportunities to members through solicitations called Requests for
Prototype Proposals (RPPs): https://mtec-sc.org/how-to-join/
• Register on the various U.S. Government / DoD grant funding platforms as
a Nontraditional Defense Contractor:
http://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title10section3014&num=0&edition=prelim
•The System for Award Management (SAM.gov) is an official website of the
U.S. Government. https://sam.gov/content/home
•There is no cost to use SAM.gov. You can use this site to:
• Register to do business with the U.S. Government
• Search for contract opportunities
• Access publicly available awards
• Understand the terms and processes, e.g.
• Technology Readiness Levels: https://mtec-sc.org/wpcontent/uploads/2016/12/TRL-definitions.pdf
• Grant application and approval process:
https://research.uga.edu/docs/units/dsc/MTEC-Proposal-PreparationGuide.pdf
• Connect with DOD leadership at USAMRDC and others like the US Military
Infectious Diseases Research Program (MIDRP); key decision-making bodies for
future solicitations; membership of MTEC facilitates this
The views expressed in this presentation are those of the author and do not necessarily reflect the official policy or position of the Department of the Army,
Department of the Navy, Department of Defense, nor the U.S. Government
23
TRAVELAN®: MARKET EXPANSION IN THE US
Supported (in part) by MTEC
➢ Immuron is pursuing a regulatory pathway to
license Travelan® with the FDA via a Biologics
License Application (BLA) with a proposed
indication to prevent TD induced by ETEC
DRUG CANDIDATE
TRAVELAN®
Status with FDA:
IND 14933
IND 15675 / IND 17066
➢ US DOD financial support (US$3.4M) to fund
part of this initiative and develop a dosing
regimen acceptable for use by the military
Plan to develop Travelan as an
approved biologic in the US targeting
travelers’ diarrhea
24
TRAVELAN® DRUG DEVELOPMENT PLAN
Travelan® current position Milestone B.
MTEC funded due to High Technology
Readiness Level (TRL) rating.
The views expressed in this presentation are those of the author and do not necessarily reflect the official policy or position of the Department of the Army,
Department of the Navy, Department of Defense, nor the U.S. Government
25
Pre-IND/IND
submission
OVERVIEW OF FDA LICENSURE PATHWAY
Pre-IND 2019
COVID
IND 2022 approval in 30 Days
Military Regulatory approval 3+ months
IRB approval/ Clinical Trial commenced May 2023
PHASE 2 TRIAL-MTEC
Optimal dosing strategy
Clinical data June 2024
End of Phase 2 meeting with FDA H2 2024
PHASE 3 (PIVOTAL) FIELD STUDY
50% efficacy
20% travelers’ diarrhea rate
10% drop-out rate
Placebo group n=293
Travelan® group n=293
IND 2025
Recruitment and clinical
trial approx. 2 Years
PHASE 3 (PIVOTAL) FIELD STUDY
50% efficacy
20% travelers’ diarrhea rate
10% drop-out rate
Placebo group n=293
Travelan® group n=293
End of Phase 3
meeting with FDA
BLA application
26
COMPANY COMPETENCIES & MANUFACTURING AND
DISTRIBUTION EXPANSION PLANS
✓ Immuron is the sole proprietary of the Travelan® product and associated intellectual property
✓ Strong US DoD collaboration
✓ Immuron has an international distribution network to ensure prompt delivery to deployed US
military if necessary
✓ All Immuron’s commercial operations involve suitably, qualified cGMP service providers that
meet the regulatory requirements of the company’s Quality Management Systems
27
COMPETITOR MARKET ANALYSIS (US)
Drug
Indication
Dosing
Average cost:
2-week trip
PRESENTLY, THERE IS NO FDA-APPROVED DRUG TO PREVENT TRAVELERS’ DIARRHEA
TRAVELAN®
Dietary supplement
3 caps (200 mg)
TID
$29.57 – 30
caplets 5
FDA-APPROVED DRUG TREATMENTS FOR DIARRHEA
PEPTO BISMOL
Relief for heartburn, nausea, indigestion, upset stomach, and diarrhea
2 tabs QID
$20.94 1
IMMODIUM
Decrease the frequency of diarrhea in TD, gastroenteritis, inflammatory bowel
disease, and short bowel syndrome
2 tabs (2 mg)
$22.00 2
CIPROFLOXACIN
Bacterial infections
500 mg
Treatment of travelers’ diarrhea
3 caps (200 mg)
TID
RIFAXIMIN
(2x24 caplets)
$59.92 3
(2x 5-day supply)
$778.10 4
(without insurance)
International Society of Travel Medicine, 2017 guidelines for treating travelers’ diarrhea included:
•
Antibiotics should NOT be used routinely, except in patients at high risk of complications
•
Rifaximin recommended when antibiotic prophylaxis is indicated
•
Fluoroquinolones not recommended for prophylaxis
•
Insufficient evidence to recommend prebiotics or probiotics
1.
2.
3.
4.
5.
Amazon.com
Amazon.com
Amazon.com (Cipro)
Amazon.com (Xifaxan)
Amazon.com
28
US SALES FORECAST FOR TRAVELAN®:
IF FDA APPROVED
MARKET POTENTIAL FOR TRAVELAN® SALES:
USD >$100 MILLION
Market potential figure derived from:
November 2023 figures of US citizens traveling to high-risk
destinations for TD (60 million)1 and obtaining pre-travel advice
(24 million)2. Sources of pre-travel advice include primary care
providers, travel medicine specialists, company doctors,
pharmacists, and travel agencies2. Our forecast utilizes a
conservative estimate for % of US citizens purchasing Travelan®
after seeking pre-travel advice.
1.
2.
U.S. Department of Commerce, International Trade Administration: U.S. International Air Travel Statistics (I-92 data),
Monthly U.S. Outbound Data, U.S. Outbound Travel to World Regions. Available at: https://www.trade.gov/usinternational-air-travel-statistics-i-92-data
2. Mathyas Wang , MD , Thomas D. Szucs , MD, MBA, MPH, LLM , and Robert Steffen , MD. Economic Aspects of
Travelers ’ Diarrhea. Journal of Travel Medicine, Volume 15, Issue 2, 2008, 110–118
Regulatory
Authority
Regulatory
Pathway
Indications
Australia
Therapeutic
Goods
Administration
(TGA)
Australian Register for
Therapeutic Goods (ARTG)
• Reduces the risk of travelers’
diarrhea
• Reduces the symptoms of
minor gastrointestinal
disorders
Health Canada
Oral Natural Health Product
(2013)
NPN 80046016
• Helps reduce the risk of
travelers’ diarrhea
Food and Drug
Administration
FDA (US)
Dietary Supplement
(2015)
Helps reduce the risk of
Travelers’ diarrhea
FDA
(US)
Biologics License
Application
• Reduces the risk of travelers’
diarrhea
• Reduces the symptoms of
minor gastrointestinal
disorders
Listed Oral Medicine
(2004)
AUST L 106709
(on completion of Phase 3
field studies)
29
THANK YOU
Collaborators:
Immuron team
ARMED FORCES
RESEARCH INSTITUTE
OF MEDICAL SCIENCES
NAVAL MEDICAL
RESEARCH
COMMAND
UNIFORMED
SERVICES
UNIVERSITY
Funding support
30
SCIENTIFIC REFERENCES
Travelan® (IMM-124E)
Travelan® has been shown to reduce both the incidence and severity of ETEC-induced diarrhea in up to 90%
of volunteers
Scandinavian Journal of Gastroenterology, 46:7-8, 862-868, DOI:
10.3109/00365521.2011.574726
Clinical Evaluation of Travelan® an Oral Prophylactic for Prevention of Travelers’ Diarrhea in Active Duty
Military Service Assigned Abroad.
Military Health System Research Symposium 14-17 Aug 2023_Abstract 1
Travelan as a broad Spectrum anti-bacterial
Immuron Limited, 29 April, 2011
Travelan® demonstrates broad reactivity to Vibrio cholera strains from Southeast Asia indicating broad
potential for prevention of traveler’s diarrhea
US Department of Defense, Armed Forces Research Institute of Medical Sciences
(AFRIM), 4 September, 2019
Travelan® prevented clinical shigellosis (bacillary dysentery) in 75% of Travelan® treated animals compared
to placebo and demonstrated a significant clinical benefit
US Department of Defense,
Share your feedback
Discover